Metabolic

Metabolic Research, Inc. Reports Profitable 1st Quarter

Business Wire May 21

Metabolic Research, Inc. (OTC:MTBR) reported a first quarter profit in its 10Q filing. The first quarter 2009 sales of $791,410 resulted in a net profit of $229,279 compared with a first quarter 2008 loss of ($146,165) on sales of $186,036. Metabolic

Metabolic Solutions raises $10M for diabetes program

FierceBiotech May 13

Kalamazoo, MI-based Metabolic Solutions Development has raised more than $9 million from private investors and $1.3 million from the NIH to fund development of a new diabetes therapy. "It's nice to have a strong market, but if we can keep...

Metabolic Research, Inc. to Be Featured on Corporate-Strategies Radio Show with Tim Connolly

Business Wire Apr 30

Metabolic Research, Inc. (OTC: MTBR) will be featured on the Corporate-Strategies Radio Show Friday morning 9:30 Eastern time to speak about Stemulite. Tia Owen, chief operating officer, Bob Bakkar, CEO, and KC Quintana will speak about Stemulite, a

Metabolic Research, Inc. Expands Science Advisory Board

Business Wire Apr 15

Metabolic Research, Inc. (OTC: MTBR) announced the expansion of its Science Advisory Board. Dr. Marvell Scott, MD, CSCS, has been appointed to the Company’s Science Advisory Board. Dr. Scott is a New York State licensed, nationally board certified

Bad Marriages Harder on Women's Health

BusinessWeek Mar 5

FDA puts to rest notion of metabolic syndrome indication for Acomplia, other weight loss drugs

Pharma's Cutting Edge Feb 15

Following FDA's non-approvable decision for rimonabant (Acomplia) last year, I referred to Sanofi-Aventis' pursuit of an indication for the metabolic syndrome as "kakameyme". Seems like FDA's Metabolic and Endocrine Division (DMEDP) agrees with...

Suggest other news sources for this topic


	Suggest a News Source Topic Top news source/blog that we're missing Why do you recommend this news source? Close Thanks for your suggestion!

Worried about pump and dump?

We review changes
for stock spam

» read more

Want to make Wikinvest better?

We need your help,
contribute today

» learn how

Do you write software?

We are recruiting
the best engineers

» view jobs

Like Wikinvest?

Spread the word —
Tell your friends!

» spread the word

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.